Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Fig. 3

On-treatment bTMB dynamics showed complementary value for predicting immunotherapy plus chemotherapy benefit. Patients with ∆bTMB ≥0 had significantly shorter PFS (A) and OS (B) than those with ∆bTMB <0. (C) patients with ∆bTMB ≥0 had higher on-treatment bTMB than those with ∆bTMB <0. (D) ∆bTMB was correlated with on-treatment bTMB. Combination of on-treatment bTMB and ∆bTMB divided patients into three groups with distinct clinical outcomes: patients with low on-treatment bTMB and ∆bTMB <0 had the longest PFS (E) and OS (F), those with low on-treatment bTMB and ∆bTMB <0 or ∆bTMB ≥0 had intermediate PFS (E) and OS (F), and those with high on-treatment bTMB and ∆bTMB ≥0 had the worst PFS (E) and OS (F)

Back to article page

Molecular Cancer

ISSN: 1476-4598